Context Therapeutics (CNTX) Corporate presentation summary

Pipeline and strategy

• Advancing T cell engager (TCE) bispecific antibodies targeting Claudin 6 (CLDN6) and Nectin-4 for solid tumors, with a focus on platinum-resistant ovarian cancer and other high-prevalence indications.

• CTIM-76 (CLDN6 x CD3) and CT-202 (Nectin-4 x CD3) are lead programs, both designed for high selectivity and tumor-specific activation.

• Strategy leverages clinically validated tumor antigens, limited competition, and high-affinity CD3 engagement to maximize solid tumor response.

• Fast Track Designation granted for CTIM-76 in platinum-resistant ovarian cancer.

• Anticipated milestones include Phase 1b initiation for CTIM-76 in Q1 2027 and initial Phase 1a data for CT-202 in 2H 2027.

Clinical data and efficacy

• CTIM-76 demonstrated a 29% overall response rate and 57% disease control rate in heavily pretreated platinum-resistant ovarian cancer patients, with low rates of cytokine release syndrome (CRS).

• Tumor shrinkage observed across multiple lesions and patients, with emerging durability signals and manageable safety profile.

• CTIM-76 showed dose-proportional anti-tumor activity and favorable pharmacokinetics, supporting both weekly and every-three-week dosing strategies.

• Safety analysis revealed most adverse events were low grade, reversible, and occurred early in treatment.

• Case studies highlighted significant tumor reduction and biomarker response in individual patients.

Market opportunity and competitive landscape

• CLDN6 and Nectin-4 therapies have the potential to address over 50,000 and 125,000 patients per year, respectively, in the US relapse/refractory setting.

• No approved treatments specifically target CLDN6+ platinum-resistant ovarian cancer, representing a significant unmet need.

• CTIM-76 and CT-202 are positioned for both monotherapy and combination strategies, including with ADCs and chemotherapy.

• Competitive analysis shows CTIM-76 and CT-202 offer differentiated profiles with conditional activation, avidity enhancement, and high potency compared to other TCEs.

• Recent TCE approvals in oncology have demonstrated strong commercial launches and revenue potential.